iBio (NYSEMKT:IBIO) jumps 14% premarket on the heels of selecting IBIO-201, a proprietary lichenase carrier molecule (branded as LickM) fused to a coronavirus subunit protein, as its leading candidate for the prevention of SARS-CoV-2 infection.
The Company previously announced that preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute (IDRI), induced anti-SARS-CoV-2 antibodies.
Additional data from cell-based pseudovirus neutralization assay testing demonstrate that IBIO-201 induced the production of more anti-spike neutralizing antibodies than IBIO-200 in immunized mice.
iBio continues to work with IDRI and the Texas A&M University System, and expects to engage additional collaborators for further characterization and testing of IBIO-201 prior to performing GLP toxicology studies.
Previously: IBio rallies on advancement of COVID-19 vaccine program (Aug. 10)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.